Search results for "Moda"

showing 10 items of 1753 documents

Reyes, moda y legislación jurídica en la España moderna

2000

NoblezaCasa RealUNESCO::HISTORIA::Historia por especialidades::Historia del arteIndumentariaDerecho social:HISTORIA::Historia por especialidades::Historia del arte [UNESCO]Moda
researchProduct

Significant Moments in a Couple Therapy Session: Towards the Integration of Different Modalities of Analysis

2020

This chapter presents a couple therapy session from four different research perspectives: The verbal dialogue was analysed with the Dialogical Investigations of Happenings of Change method, the embodied reactions of each participant were analysed by examining the electrodermal activity of each participant, and nonverbal synchrony was observed between the participants. Stimulated Recall Interviews, conducted individually after the session, were used to gain insights on the participants’ thoughts and feelings concerning particular moments in the session. We wished to determine what could be learned from the embodied reactions of the participants in couple therapy, including whether the data o…

Nonverbal communicationModalitiesFeelingEmbodied cognitionStimulated recallmedia_common.quotation_subjectDialogical selfSession (computer science)PsychologyhumanitiesCognitive psychologymedia_common
researchProduct

A precise measurement of the Z resonance parameters through its hadronic decays

1990

A measurement of the cross section for e+e-→ hadrons using 11 000 hadronic decays of the Z boson at ten different center-of-mass energies is presented. A three-parameter fit gives the following values for the Z mass MZ, the total width ΓZ, the product of the electronic and hadronic partial widths ΓeΓh, and the unfolded pole cross section σ0: MZ = 91.171 ± 0.030 (stat.) ± 0.030 (beam) GeV, ΓZ = 2.511 ± 0.065 GeV, ΓeΓh = 0.148 ± 0.006 (stat.) ± 0.004 (syst.) GeV2, σ0 = 41.6 ± 0.7 (stat.) ± 1.1 (syst.) nb, Good agreement with the predictions of the standard model is observed. From a two-parameter fit the number of massless neutrino generations is found to be Nv = 2.91 ± 0.26. Thus the hypothes…

Nuclear and High Energy PhysicsParticle physics[PHYS.HEXP] Physics [physics]/High Energy Physics - Experiment [hep-ex]pragmatismtruthElectron–positron annihilationHadronfictionpossible worlds01 natural sciencesResonance (particle physics)webStandard ModelRDFNuclear physicsCross section (physics)semantic webesthetics0103 physical sciencesmemetic[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsNuclear Experimentmetalanguagemodal logicPhysicsInternet010308 nuclear & particles physicstrust3. Good healthMassless particlePhysique des particules élémentairesHigh Energy Physics::ExperimentFísica nuclearNeutrinoBeam (structure)Particle Physics - Experiment
researchProduct

The fusion-fission process in the reaction 34S+186W near the interaction barrier

2014

International audience; The reaction 34S + 186W at Elab=160 MeV was investigated with the aim of diving into the features of thefusion-fission process. Gamma rays in coincidence with binary reaction fragments were measured using the high efficiencygamma-ray spectrometer ORGAM at the TANDEM Accelerator facility of I.P.N., Orsay, and the time-of-flight spectrometerfor fission fragments (FF) registration CORSET of the Flerov Laboratory of Nuclear Reactions (FLNR), Dubna. The couplingof the ORGAM and CORSET setups offers the unique opportunity of extracting details for characterizing the fusion-fissionprocess and gives information regarding production of neutron-rich heavy nuclei. The FF-$\gamm…

Nuclear reactionPhysicsSpectrometerFissionAstrophysics::High Energy Astrophysical PhenomenaNuclear TheoryGamma ray020206 networking & telecommunications02 engineering and technology[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]7. Clean energyCoincidenceNuclear physicsmulti-modal fissiongamma spectroscopy0202 electrical engineering electronic engineering information engineeringshell effects020201 artificial intelligence & image processingNeutronGamma spectroscopyNuclear ExperimentNucleonFusion-fission
researchProduct

A correction method for the analysis of continuous linear one-dimensional systems under moving loads

2008

A new correction procedure for dynamic analysis of linear, proportionally damped, continuous systems under traveling concentrated loads is proposed; both cases of non-parametric (moving forces) and parametric (moving mass) loads are considered. Improvement in the evaluation of the dynamic response is obtained by separating the contribution of the low-frequency (LF) modes from that of the high-frequency (HF) modes. The former is calculated, as usual, by classical modal analysis, while the latter is taken into account using a new series expansion of the corresponding particular solution. The advantage of the suggested method is immediately shown in the calculation of the stress distribution s…

OSCILLATORAcoustics and UltrasonicsModal analysisClassification of discontinuitiesACCELERATIONMASS PROBLEMCalculusMathematicsParametric statisticsAdded massDYNAMIC-ANALYSISSeries (mathematics)VIBRATIONMechanical EngineeringTIMOSHENKO BEAMMathematical analysisMoving loadCondensed Matter PhysicsMethod of undetermined coefficientsMODE SUPERPOSITION ANALYSISCALCULATING BENDING MOMENTMechanics of MaterialsSHEAR FORCESeries expansionSettore ICAR/08 - Scienza Delle CostruzioniBRIDGES
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

2015

Abstract Purpose: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiologic markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in women with triple-negative breast cancer (TNBC). Experimental Design: Fifty consecutive women with TNBC and an indication for NAC were prospectively included. Different pretreatment clinical, biologic, and pathologic biomarkers, including SBR grade, the Ki-67 proliferation index, androgen receptor expression, EGF receptor (EGFR), and cytokeratin 5/6 staining, were assessed. Tumor glucose metabolism at baseline and its chan…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyProliferation indexmedicine.medical_treatmentBiopsyTriple Negative Breast NeoplasmsBreast cancerFluorodeoxyglucose F18Internal medicineBiopsyAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansEpidermal growth factor receptorTriple-negative breast cancerNeoadjuvant therapyAgedNeoplasm StagingChemotherapymedicine.diagnostic_testbiologybusiness.industryOdds ratioMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyNeoadjuvant TherapyTumor BurdenGlucoseTreatment OutcomeOncologyROC CurveLymphatic MetastasisPositron-Emission Tomographybiology.proteinFemaleNeoplasm GradingbusinessTomography X-Ray ComputedBiomarkersClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Neoadjuvant therapy for breast cancer

2019

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic…

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsSettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerInternal medicineCancer screeningmedicineBiomarkers TumorOdds RatioMammographyHumans030212 general & internal medicineneoadjuvant therapyNeoadjuvant therapyTriple-negative breast cancerTumor markerCancer stagingAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyCancer registryTreatment OutcomeOncology030220 oncology & carcinogenesisFemalemultidisciplinaryMammography
researchProduct

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

2010

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed. Six germ cell tumor patients provided informed consent and were included in the compassionate use program. All patients were heavily pretreated, with a median of 3.5 prior lines of therapy. All failed prior mobilization with G-CSF in combination with chemotherapy. Five patien…

OncologyAdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesPlatelet Engraftmentmedicine.medical_treatmentCD34Hematopoietic stem cell transplantationCyclamsYoung AdultTesticular NeoplasmsHeterocyclic CompoundsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansUltrasonographyTransplantationChemotherapyMobilizationbusiness.industryPlerixaforHematopoietic Stem Cell TransplantationHematologyMiddle AgedNeoplasms Germ Cell and EmbryonalCombined Modality TherapyHematopoietic Stem Cell MobilizationSurgerySeminomamedicine.anatomical_structureStem cellbusinessGerm cellmedicine.drugBone marrow transplantation
researchProduct